Sophia Kessabi

Exploring the Impact of Infusion Frequency in Hemophilia A: Exit Interviews with Patients Participating in BAY 94-9027 Extension Studies (PROTECT VIII)

Jane R. Wells, Adam Gater, Chris Marshall et al. · Patient · 2019 · 31 citations · Full text

Medicine, Hematology, Pharmacotherapy +15

Effect of non-persistent use of oral glucose-lowering drugs on HbA_1cgoal attainment

Fernie J. A. Penning‐van Beest, Sjoukje van der Bij, Joëlle A. Erkens et al. · Current Medical Research and Opinion · 2008 · 25 citations

Medicine, Clinical Pharmacy, Pharmacology +17

Assessing the Consequences of External Reference Pricing for Global Access to Medicines and Innovation: Economic Analysis and Policy Implications

András Incze, Zoltán Kaló, Jaime Espín et al. · Frontiers in Pharmacology · 2022 · 18 citations · Full text

Pharmacy, Health Policy, Pharmaceutical Policy +17

Change of initial oral antidiabetic therapy in type 2 diabetic patients

Arian Plat, Fernie Penning-van Beest, Sophia Kessabi et al. · Pharmacy World & Science · 2009 · 16 citations · Full text

Medicine, Pharmacotherapy, Diabetology +12

<p>Matching-adjusted indirect comparisons of annualized bleeding rate and utilization of BAY 94-9027 versus three recombinant factor VIII agents for prophylaxis in patients with severe hemophilia A</p>

Katharine Batt, Wei Gao, Rajeev Ayyagari et al. · Journal of Blood Medicine · 2019 · 14 citations · Full text

Medicine, Hematology, Pharmacotherapy +17